179 related articles for article (PubMed ID: 20503412)
1. Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4.
Robertson FM; Simeone AM; Lucci A; McMurray JS; Ghosh S; Cristofanilli M
Cancer; 2010 Jun; 116(11 Suppl):2806-14. PubMed ID: 20503412
[TBL] [Abstract][Full Text] [Related]
2. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells.
Robertson FM; Simeone AM; Mazumdar A; Shah AH; McMurray JS; Ghosh S; Cristofanilli M
J Exp Ther Oncol; 2008; 7(4):299-312. PubMed ID: 19227010
[TBL] [Abstract][Full Text] [Related]
3. Regulation of expression of matrix metalloproteinase-9 in early human T cells of the HSB.2 cultured line by the EP3 subtype of prostaglandin E2 receptor.
Zeng L; An S; Goetzl EJ
J Biol Chem; 1996 Nov; 271(44):27744-50. PubMed ID: 8910368
[TBL] [Abstract][Full Text] [Related]
4. The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function.
Iyú D; Glenn JR; White AE; Johnson AJ; Fox SC; Heptinstall S
Platelets; 2010; 21(5):329-42. PubMed ID: 20433310
[TBL] [Abstract][Full Text] [Related]
5. GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist.
Wilson RJ; Giblin GM; Roomans S; Rhodes SA; Cartwright KA; Shield VJ; Brown J; Wise A; Chowdhury J; Pritchard S; Coote J; Noel LS; Kenakin T; Burns-Kurtis CL; Morrison V; Gray DW; Giles H
Br J Pharmacol; 2006 Jun; 148(3):326-39. PubMed ID: 16604093
[TBL] [Abstract][Full Text] [Related]
6. Opposing effects of prostaglandin E
Carboneau BA; Allan JA; Townsend SE; Kimple ME; Breyer RM; Gannon M
Mol Metab; 2017 Jun; 6(6):548-559. PubMed ID: 28580285
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E2 promotes wound-induced migration of intestinal subepithelial myofibroblasts via EP2, EP3, and EP4 prostanoid receptor activation.
Iwanaga K; Okada M; Murata T; Hori M; Ozaki H
J Pharmacol Exp Ther; 2012 Mar; 340(3):604-11. PubMed ID: 22138372
[TBL] [Abstract][Full Text] [Related]
8. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.
Timoshenko AV; Xu G; Chakrabarti S; Lala PK; Chakraborty C
Exp Cell Res; 2003 Oct; 289(2):265-74. PubMed ID: 14499627
[TBL] [Abstract][Full Text] [Related]
9. COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems.
Katoh H; Hosono K; Ito Y; Suzuki T; Ogawa Y; Kubo H; Kamata H; Mishima T; Tamaki H; Sakagami H; Sugimoto Y; Narumiya S; Watanabe M; Majima M
Am J Pathol; 2010 Mar; 176(3):1469-83. PubMed ID: 20110411
[TBL] [Abstract][Full Text] [Related]
10. Role of EP3 and EP4 prostaglandin receptors in reorganization of the cytoskeleton in mature human osteoclasts.
Sarrazin P; Hackett JA; Fortier I; Gallant MA; de Brum-Fernandes A
J Rheumatol; 2004 Aug; 31(8):1598-606. PubMed ID: 15290741
[TBL] [Abstract][Full Text] [Related]
11. Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human.
Cipollone F; Fazia ML; Iezzi A; Cuccurullo C; De Cesare D; Ucchino S; Spigonardo F; Marchetti A; Buttitta F; Paloscia L; Mascellanti M; Cuccurullo F; Mezzetti A
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1925-31. PubMed ID: 16020747
[TBL] [Abstract][Full Text] [Related]
12. Selective regulation of RNK-16 cell matrix metalloproteinases by the EP4 subtype of prostaglandin E2 receptor.
Zeng L; An S; Goetzl EJ
Biochemistry; 1996 Jun; 35(22):7159-64. PubMed ID: 8679543
[TBL] [Abstract][Full Text] [Related]
13. Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model.
Parida S; Parekh A; Dey G; Ghosh SC; Mandal M
Cancer Biol Ther; 2015; 16(6):922-32. PubMed ID: 25894216
[TBL] [Abstract][Full Text] [Related]
14. Induction of adherent activity in mastocytoma P-815 cells by the cooperation of two prostaglandin E2 receptor subtypes, EP3 and EP4.
Hatae N; Kita A; Tanaka S; Sugimoto Y; Ichikawa A
J Biol Chem; 2003 May; 278(20):17977-81. PubMed ID: 12637575
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells.
Pan MR; Hou MF; Chang HC; Hung WC
J Biol Chem; 2008 Apr; 283(17):11155-63. PubMed ID: 18319253
[TBL] [Abstract][Full Text] [Related]
16. Expression of prostaglandin E2 receptors in oral squamous cell carcinomas and growth inhibitory effects of an EP3 selective antagonist, ONO-AE3-240.
Hoshikawa H; Goto R; Mori T; Mitani T; Mori N
Int J Oncol; 2009 Mar; 34(3):847-52. PubMed ID: 19212690
[TBL] [Abstract][Full Text] [Related]
17. Dominant role of prostaglandin E2 EP4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome.
Nüsing RM; Treude A; Weissenberger C; Jensen B; Bek M; Wagner C; Narumiya S; Seyberth HW
J Am Soc Nephrol; 2005 Aug; 16(8):2354-62. PubMed ID: 15976003
[TBL] [Abstract][Full Text] [Related]
18. Growth regulation of primary human keratinocytes by prostaglandin E receptor EP2 and EP3 subtypes.
Konger RL; Malaviya R; Pentland AP
Biochim Biophys Acta; 1998 Feb; 1401(2):221-34. PubMed ID: 9531979
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin E2 Reduces Cardiac Contractility via EP3 Receptor.
Gu X; Xu J; Zhu L; Bryson T; Yang XP; Peterson E; Harding P
Circ Heart Fail; 2016 Aug; 9(8):. PubMed ID: 27502370
[TBL] [Abstract][Full Text] [Related]
20. Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.
Ogony J; Choi HJ; Lui A; Cristofanilli M; Lewis-Wambi J
Breast Cancer Res; 2016 Feb; 18(1):25. PubMed ID: 26897526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
